| 1 | account | 6,186 |
| 2 | compensate | 366 |
| 3 | qualify | 185 |
| 4 | disfavor | 9 |
| 5 | minimal/resolved | 5 |
| 6 | 3',4',5'-hydroxylated | 3 |
| 7 | auscultate | 3 |
| 8 | iro2 | 3 |
| 9 | psc-bppv | 3 |
| 10 | substages | 3 |
| 11 | supercomplexes | 3 |
| 12 | +1.62 | 2 |
| 13 | 0.59-0.62 | 2 |
| 14 | 04/2005 | 2 |
| 15 | 1.5/100,000 | 2 |
| 16 | 1.89-l | 2 |
| 17 | cis-dimerization | 2 |
| 18 | end-2005 | 2 |
| 19 | folate-mh-aunp | 2 |
| 20 | healthvault | 2 |
| 21 | mandelonitrile | 2 |
| 22 | micro-bars | 2 |
| 23 | overcompensate | 2 |
| 24 | parklands | 2 |
| 25 | risk-adjust | 2 |
| 26 | yeast-secreted | 2 |
| 27 | 'presentation | 1 |
| 28 | -3.28°c | 1 |
| 29 | -8+0 | 1 |
| 30 | 0.5ml/kg/hr | 1 |
| 31 | 0.9699 | 1 |
| 32 | 0.9903 | 1 |
| 33 | 09:33 | 1 |
| 34 | 1,3-diphosphoglycerate | 1 |
| 35 | 1.0068 | 1 |
| 36 | 1.0163 | 1 |
| 37 | 1.0396 | 1 |
| 38 | 1.1283 | 1 |
| 39 | 1.1817 | 1 |
| 40 | 1.2073 | 1 |
| 41 | 1.2145 | 1 |
| 42 | 1.2562 | 1 |
| 43 | 1.321 | 1 |
| 44 | 1.89-96 | 1 |
| 45 | 1/512 | 1 |
| 46 | 1/8192 | 1 |
| 47 | 10,000pg/ml | 1 |
| 48 | 10.232 | 1 |
| 49 | 102.5g/l | 1 |
| 50 | 105euro | 1 |
| 51 | 106,775 | 1 |
| 52 | 10ng/g | 1 |
| 53 | 11-cis-retinol | 1 |
| 54 | 11/15/96 | 1 |
| 55 | 113.34 | 1 |
| 56 | 114,124 | 1 |
| 57 | 12500µg/ml | 1 |
| 58 | 13,639 | 1 |
| 59 | 1300-fold | 1 |
| 60 | 133mls | 1 |
| 61 | 134.0±43.4mpa | 1 |
| 62 | 1562µg/ml | 1 |
| 63 | 156min/week | 1 |
| 64 | 18.0kpa | 1 |
| 65 | 18.8ml | 1 |
| 66 | 1ml/kg/hr | 1 |
| 67 | 1±0.1mm | 1 |
| 68 | 22-nm | 1 |
| 69 | 237,010 | 1 |
| 70 | 2500.00ng/ml | 1 |
| 71 | 29-month-olds | 1 |
| 72 | 3-amino-5-imino-5,8-dihydronaphthalen-2-ol | 1 |
| 73 | 3-ketohexanoyl-coa | 1 |
| 74 | 3-methyl-pyrrolines | 1 |
| 75 | 3.86mpa | 1 |
| 76 | 35.9:1 | 1 |
| 77 | 36,903 | 1 |
| 78 | 37.87hu | 1 |
| 79 | 386kpa | 1 |
| 80 | 390.4 | 1 |
| 81 | 4,6,8-triaryl-3- | 1 |
| 82 | 4.7/1 | 1 |
| 83 | 45.4±1.2 | 1 |
| 84 | 457,395 | 1 |
| 85 | 45°c-55°c | 1 |
| 86 | 45× | 1 |
| 87 | 5,6-dihydroxy-7-methoxyflavone | 1 |
| 88 | 5,8-epoxy | 1 |
| 89 | 5.072 | 1 |
| 90 | 5.880 | 1 |
| 91 | 52.5kpa | 1 |
| 92 | 555.7 | 1 |
| 93 | 6.25mm | 1 |
| 94 | 6.709 | 1 |
| 95 | 6.923 | 1 |
| 96 | 60.5±1.2 | 1 |
| 97 | 600.0ng/ml | 1 |
| 98 | 69,982 | 1 |
| 99 | 69.3mg | 1 |
| 100 | 7.44° | 1 |
| 101 | 70-72°c | 1 |
| 102 | 8,350 | 1 |
| 103 | 8.2:1 | 1 |
| 104 | 80μg/hour | 1 |
| 105 | 9α-hydroxy | 1 |
| 106 | a302 | 1 |
| 107 | account.differences | 1 |
| 108 | acupoint-moximustion | 1 |
| 109 | additive-additive | 1 |
| 110 | ak7-rag2 | 1 |
| 111 | antinauseants | 1 |
| 112 | antithrombin-treated | 1 |
| 113 | araldite | 1 |
| 114 | asa-resistant | 1 |
| 115 | atone | 1 |
| 116 | barbour-stoenner-kelly | 1 |
| 117 | be-reduced | 1 |
| 118 | biculturalism | 1 |
| 119 | big-bags | 1 |
| 120 | bromopterosine | 1 |
| 121 | canals/isthmuses | 1 |
| 122 | candied | 1 |
| 123 | carrier-doped | 1 |
| 124 | cbt1 | 1 |
| 125 | cement-30 | 1 |
| 126 | chito-oligomers | 1 |
| 127 | chromorhizae | 1 |
| 128 | citrate-phosphate-dextrose | 1 |
| 129 | considertion | 1 |
| 130 | dansylglycine | 1 |
| 131 | december2006 | 1 |
| 132 | diaminoanisole | 1 |
| 133 | dilated-hcm | 1 |
| 134 | dimethylhdrazine | 1 |
| 135 | discipline- | 1 |
| 136 | don-3-o-glucoside | 1 |
| 137 | duty/work | 1 |
| 138 | endosome/lysosomes | 1 |
| 139 | euro41,110/qaly | 1 |
| 140 | euro43,614/qaly | 1 |
| 141 | euro51,106/qaly | 1 |
| 142 | fentanyl-xylazine | 1 |
| 143 | four-round | 1 |
| 144 | gangs | 1 |
| 145 | goas | 1 |
| 146 | graphitic-like | 1 |
| 147 | grk2-dependent | 1 |
| 148 | half-height | 1 |
| 149 | hbe-16 | 1 |
| 150 | hdl-phosphatidylcholine | 1 |
| 151 | high-volume/low-pressure | 1 |
| 152 | high/upper-middle | 1 |
| 153 | higher-skilled | 1 |
| 154 | highly-ordered | 1 |
| 155 | hypopnoeas | 1 |
| 156 | immunoprecipitable | 1 |
| 157 | intensity-invariant | 1 |
| 158 | intervention-driven | 1 |
| 159 | intestinalized | 1 |
| 160 | irregular-shapes | 1 |
| 161 | juggle | 1 |
| 162 | karma-deed-heredity | 1 |
| 163 | krn7000 | 1 |
| 164 | macaque- | 1 |
| 165 | masticate | 1 |
| 166 | met+pio30 | 1 |
| 167 | metabolic/digestive | 1 |
| 168 | metastic | 1 |
| 169 | microsticks | 1 |
| 170 | mid-sternotomy | 1 |
| 171 | miltiradiene | 1 |
| 172 | mitophagosomes | 1 |
| 173 | mpeg2 | 1 |
| 174 | murrayazolinine | 1 |
| 175 | n-methyl-p-phenylenediamine | 1 |
| 176 | na2ca | 1 |
| 177 | ndsr | 1 |
| 178 | nitrosatability | 1 |
| 179 | nod/scid/γ-null | 1 |
| 180 | non-tcfas | 1 |
| 181 | nonimmersed | 1 |
| 182 | noti-cut | 1 |
| 183 | oblivion | 1 |
| 184 | od+hp | 1 |
| 185 | over-correct | 1 |
| 186 | pcdna3.0 | 1 |
| 187 | per-doctor | 1 |
| 188 | petroleum-like | 1 |
| 189 | phenythoin | 1 |
| 190 | placebo.implications | 1 |
| 191 | placebo/peginterferon-alfa-2a/ribavirin | 1 |
| 192 | polidesossiribonucleotide | 1 |
| 193 | poly-alpha-olefin | 1 |
| 194 | postchanges | 1 |
| 195 | pound124 | 1 |
| 196 | pound596 | 1 |
| 197 | pre-graduate | 1 |
| 198 | previously-unconsidered | 1 |
| 199 | prostaglandin-endoperoxides | 1 |
| 200 | puiggrós | 1 |
| 201 | renal-ablated | 1 |
| 202 | reperfusion-era | 1 |
| 203 | rfviii-water | 1 |
| 204 | ribozyme-catalyzed | 1 |
| 205 | schizoites | 1 |
| 206 | scytonemin-rich | 1 |
| 207 | sepsis/dic | 1 |
| 208 | set-i | 1 |
| 209 | side-lining | 1 |
| 210 | silicoarsenates | 1 |
| 211 | simmer | 1 |
| 212 | smokers/ex-smokers/non-smokers | 1 |
| 213 | sorafenib-cryorx | 1 |
| 214 | subqualities | 1 |
| 215 | therapeutic/treatment-oriented | 1 |
| 216 | thiopental-rocuronium | 1 |
| 217 | time-to-ecg | 1 |
| 218 | usd8 | 1 |
| 219 | water-preferring | 1 |
| 220 | yr=0 | 1 |
| 221 | zinc-aluminum-layered | 1 |
| 222 | zt9 | 1 |
| 223 | £143 | 1 |
| 224 | £2204 | 1 |
| 225 | £3480 | 1 |
| 226 | £4.18 | 1 |
| 227 | £62 | 1 |
| 228 | β-hydroxyynones | 1 |
| 229 | β-pbo | 1 |
| 230 | €14,350 | 1 |
| 231 | €26,000 | 1 |
| 1 | 'presentation | 1 |
| 2 | +1.62 | 2 |
| 3 | -3.28°c | 1 |
| 4 | -8+0 | 1 |
| 5 | 0.59-0.62 | 2 |
| 6 | 0.5ml/kg/hr | 1 |
| 7 | 0.9699 | 1 |
| 8 | 0.9903 | 1 |
| 9 | 04/2005 | 2 |
| 10 | 09:33 | 1 |
| 11 | 1,3-diphosphoglycerate | 1 |
| 12 | 1.0068 | 1 |
| 13 | 1.0163 | 1 |
| 14 | 1.0396 | 1 |
| 15 | 1.1283 | 1 |
| 16 | 1.1817 | 1 |
| 17 | 1.2073 | 1 |
| 18 | 1.2145 | 1 |
| 19 | 1.2562 | 1 |
| 20 | 1.321 | 1 |
| 21 | 1.5/100,000 | 2 |
| 22 | 1.89-96 | 1 |
| 23 | 1.89-l | 2 |
| 24 | 1/512 | 1 |
| 25 | 1/8192 | 1 |
| 26 | 10,000pg/ml | 1 |
| 27 | 10.232 | 1 |
| 28 | 102.5g/l | 1 |
| 29 | 105euro | 1 |
| 30 | 106,775 | 1 |
| 31 | 10ng/g | 1 |
| 32 | 11-cis-retinol | 1 |
| 33 | 11/15/96 | 1 |
| 34 | 113.34 | 1 |
| 35 | 114,124 | 1 |
| 36 | 12500µg/ml | 1 |
| 37 | 13,639 | 1 |
| 38 | 1300-fold | 1 |
| 39 | 133mls | 1 |
| 40 | 134.0±43.4mpa | 1 |
| 41 | 1562µg/ml | 1 |
| 42 | 156min/week | 1 |
| 43 | 18.0kpa | 1 |
| 44 | 18.8ml | 1 |
| 45 | 1ml/kg/hr | 1 |
| 46 | 1±0.1mm | 1 |
| 47 | 22-nm | 1 |
| 48 | 237,010 | 1 |
| 49 | 2500.00ng/ml | 1 |
| 50 | 29-month-olds | 1 |
| 51 | 3',4',5'-hydroxylated | 3 |
| 52 | 3-amino-5-imino-5,8-dihydronaphthalen-2-ol | 1 |
| 53 | 3-ketohexanoyl-coa | 1 |
| 54 | 3-methyl-pyrrolines | 1 |
| 55 | 3.86mpa | 1 |
| 56 | 35.9:1 | 1 |
| 57 | 36,903 | 1 |
| 58 | 37.87hu | 1 |
| 59 | 386kpa | 1 |
| 60 | 390.4 | 1 |
| 61 | 4,6,8-triaryl-3- | 1 |
| 62 | 4.7/1 | 1 |
| 63 | 45.4±1.2 | 1 |
| 64 | 457,395 | 1 |
| 65 | 45°c-55°c | 1 |
| 66 | 45× | 1 |
| 67 | 5,6-dihydroxy-7-methoxyflavone | 1 |
| 68 | 5,8-epoxy | 1 |
| 69 | 5.072 | 1 |
| 70 | 5.880 | 1 |
| 71 | 52.5kpa | 1 |
| 72 | 555.7 | 1 |
| 73 | 6.25mm | 1 |
| 74 | 6.709 | 1 |
| 75 | 6.923 | 1 |
| 76 | 60.5±1.2 | 1 |
| 77 | 600.0ng/ml | 1 |
| 78 | 69,982 | 1 |
| 79 | 69.3mg | 1 |
| 80 | 7.44° | 1 |
| 81 | 70-72°c | 1 |
| 82 | 8,350 | 1 |
| 83 | 8.2:1 | 1 |
| 84 | 80μg/hour | 1 |
| 85 | 9α-hydroxy | 1 |
| 86 | a302 | 1 |
| 87 | account | 6,186 |
| 88 | account.differences | 1 |
| 89 | acupoint-moximustion | 1 |
| 90 | additive-additive | 1 |
| 91 | ak7-rag2 | 1 |
| 92 | antinauseants | 1 |
| 93 | antithrombin-treated | 1 |
| 94 | araldite | 1 |
| 95 | asa-resistant | 1 |
| 96 | atone | 1 |
| 97 | auscultate | 3 |
| 98 | barbour-stoenner-kelly | 1 |
| 99 | be-reduced | 1 |
| 100 | biculturalism | 1 |
| 101 | big-bags | 1 |
| 102 | bromopterosine | 1 |
| 103 | canals/isthmuses | 1 |
| 104 | candied | 1 |
| 105 | carrier-doped | 1 |
| 106 | cbt1 | 1 |
| 107 | cement-30 | 1 |
| 108 | chito-oligomers | 1 |
| 109 | chromorhizae | 1 |
| 110 | cis-dimerization | 2 |
| 111 | citrate-phosphate-dextrose | 1 |
| 112 | compensate | 366 |
| 113 | considertion | 1 |
| 114 | dansylglycine | 1 |
| 115 | december2006 | 1 |
| 116 | diaminoanisole | 1 |
| 117 | dilated-hcm | 1 |
| 118 | dimethylhdrazine | 1 |
| 119 | discipline- | 1 |
| 120 | disfavor | 9 |
| 121 | don-3-o-glucoside | 1 |
| 122 | duty/work | 1 |
| 123 | end-2005 | 2 |
| 124 | endosome/lysosomes | 1 |
| 125 | euro41,110/qaly | 1 |
| 126 | euro43,614/qaly | 1 |
| 127 | euro51,106/qaly | 1 |
| 128 | fentanyl-xylazine | 1 |
| 129 | folate-mh-aunp | 2 |
| 130 | four-round | 1 |
| 131 | gangs | 1 |
| 132 | goas | 1 |
| 133 | graphitic-like | 1 |
| 134 | grk2-dependent | 1 |
| 135 | half-height | 1 |
| 136 | hbe-16 | 1 |
| 137 | hdl-phosphatidylcholine | 1 |
| 138 | healthvault | 2 |
| 139 | high-volume/low-pressure | 1 |
| 140 | high/upper-middle | 1 |
| 141 | higher-skilled | 1 |
| 142 | highly-ordered | 1 |
| 143 | hypopnoeas | 1 |
| 144 | immunoprecipitable | 1 |
| 145 | intensity-invariant | 1 |
| 146 | intervention-driven | 1 |
| 147 | intestinalized | 1 |
| 148 | iro2 | 3 |
| 149 | irregular-shapes | 1 |
| 150 | juggle | 1 |
| 151 | karma-deed-heredity | 1 |
| 152 | krn7000 | 1 |
| 153 | macaque- | 1 |
| 154 | mandelonitrile | 2 |
| 155 | masticate | 1 |
| 156 | met+pio30 | 1 |
| 157 | metabolic/digestive | 1 |
| 158 | metastic | 1 |
| 159 | micro-bars | 2 |
| 160 | microsticks | 1 |
| 161 | mid-sternotomy | 1 |
| 162 | miltiradiene | 1 |
| 163 | minimal/resolved | 5 |
| 164 | mitophagosomes | 1 |
| 165 | mpeg2 | 1 |
| 166 | murrayazolinine | 1 |
| 167 | n-methyl-p-phenylenediamine | 1 |
| 168 | na2ca | 1 |
| 169 | ndsr | 1 |
| 170 | nitrosatability | 1 |
| 171 | nod/scid/γ-null | 1 |
| 172 | non-tcfas | 1 |
| 173 | nonimmersed | 1 |
| 174 | noti-cut | 1 |
| 175 | oblivion | 1 |
| 176 | od+hp | 1 |
| 177 | over-correct | 1 |
| 178 | overcompensate | 2 |
| 179 | parklands | 2 |
| 180 | pcdna3.0 | 1 |
| 181 | per-doctor | 1 |
| 182 | petroleum-like | 1 |
| 183 | phenythoin | 1 |
| 184 | placebo.implications | 1 |
| 185 | placebo/peginterferon-alfa-2a/ribavirin | 1 |
| 186 | polidesossiribonucleotide | 1 |
| 187 | poly-alpha-olefin | 1 |
| 188 | postchanges | 1 |
| 189 | pound124 | 1 |
| 190 | pound596 | 1 |
| 191 | pre-graduate | 1 |
| 192 | previously-unconsidered | 1 |
| 193 | prostaglandin-endoperoxides | 1 |
| 194 | psc-bppv | 3 |
| 195 | puiggrós | 1 |
| 196 | qualify | 185 |
| 197 | renal-ablated | 1 |
| 198 | reperfusion-era | 1 |
| 199 | rfviii-water | 1 |
| 200 | ribozyme-catalyzed | 1 |
| 201 | risk-adjust | 2 |
| 202 | schizoites | 1 |
| 203 | scytonemin-rich | 1 |
| 204 | sepsis/dic | 1 |
| 205 | set-i | 1 |
| 206 | side-lining | 1 |
| 207 | silicoarsenates | 1 |
| 208 | simmer | 1 |
| 209 | smokers/ex-smokers/non-smokers | 1 |
| 210 | sorafenib-cryorx | 1 |
| 211 | subqualities | 1 |
| 212 | substages | 3 |
| 213 | supercomplexes | 3 |
| 214 | therapeutic/treatment-oriented | 1 |
| 215 | thiopental-rocuronium | 1 |
| 216 | time-to-ecg | 1 |
| 217 | usd8 | 1 |
| 218 | water-preferring | 1 |
| 219 | yeast-secreted | 2 |
| 220 | yr=0 | 1 |
| 221 | zinc-aluminum-layered | 1 |
| 222 | zt9 | 1 |
| 223 | £143 | 1 |
| 224 | £2204 | 1 |
| 225 | £3480 | 1 |
| 226 | £4.18 | 1 |
| 227 | £62 | 1 |
| 228 | β-hydroxyynones | 1 |
| 229 | β-pbo | 1 |
| 230 | €14,350 | 1 |
| 231 | €26,000 | 1 |
| 1 | 4,6,8-triaryl-3- | 1 |
| 2 | discipline- | 1 |
| 3 | macaque- | 1 |
| 4 | -8+0 | 1 |
| 5 | pcdna3.0 | 1 |
| 6 | 1.5/100,000 | 2 |
| 7 | €26,000 | 1 |
| 8 | krn7000 | 1 |
| 9 | 237,010 | 1 |
| 10 | cement-30 | 1 |
| 11 | met+pio30 | 1 |
| 12 | €14,350 | 1 |
| 13 | 8,350 | 1 |
| 14 | £3480 | 1 |
| 15 | 5.880 | 1 |
| 16 | yr=0 | 1 |
| 17 | 4.7/1 | 1 |
| 18 | 1.321 | 1 |
| 19 | 8.2:1 | 1 |
| 20 | 35.9:1 | 1 |
| 21 | cbt1 | 1 |
| 22 | 45.4±1.2 | 1 |
| 23 | 60.5±1.2 | 1 |
| 24 | a302 | 1 |
| 25 | 1/512 | 1 |
| 26 | 10.232 | 1 |
| 27 | 0.59-0.62 | 2 |
| 28 | +1.62 | 2 |
| 29 | 1.2562 | 1 |
| 30 | £62 | 1 |
| 31 | 5.072 | 1 |
| 32 | 69,982 | 1 |
| 33 | 1/8192 | 1 |
| 34 | ak7-rag2 | 1 |
| 35 | mpeg2 | 1 |
| 36 | iro2 | 3 |
| 37 | 36,903 | 1 |
| 38 | 0.9903 | 1 |
| 39 | 6.923 | 1 |
| 40 | 09:33 | 1 |
| 41 | £143 | 1 |
| 42 | 1.0163 | 1 |
| 43 | 1.2073 | 1 |
| 44 | 1.1283 | 1 |
| 45 | 390.4 | 1 |
| 46 | £2204 | 1 |
| 47 | 114,124 | 1 |
| 48 | pound124 | 1 |
| 49 | 113.34 | 1 |
| 50 | end-2005 | 2 |
| 51 | 04/2005 | 2 |
| 52 | 1.2145 | 1 |
| 53 | 106,775 | 1 |
| 54 | 457,395 | 1 |
| 55 | december2006 | 1 |
| 56 | hbe-16 | 1 |
| 57 | 1.89-96 | 1 |
| 58 | 11/15/96 | 1 |
| 59 | 1.0396 | 1 |
| 60 | pound596 | 1 |
| 61 | 555.7 | 1 |
| 62 | 1.1817 | 1 |
| 63 | £4.18 | 1 |
| 64 | 1.0068 | 1 |
| 65 | usd8 | 1 |
| 66 | 6.709 | 1 |
| 67 | 13,639 | 1 |
| 68 | 0.9699 | 1 |
| 69 | zt9 | 1 |
| 70 | na2ca | 1 |
| 71 | 3-ketohexanoyl-coa | 1 |
| 72 | 18.0kpa | 1 |
| 73 | 52.5kpa | 1 |
| 74 | 386kpa | 1 |
| 75 | 134.0±43.4mpa | 1 |
| 76 | 3.86mpa | 1 |
| 77 | reperfusion-era | 1 |
| 78 | sepsis/dic | 1 |
| 79 | metastic | 1 |
| 80 | 70-72°c | 1 |
| 81 | 45°c-55°c | 1 |
| 82 | -3.28°c | 1 |
| 83 | be-reduced | 1 |
| 84 | candied | 1 |
| 85 | higher-skilled | 1 |
| 86 | carrier-doped | 1 |
| 87 | previously-unconsidered | 1 |
| 88 | highly-ordered | 1 |
| 89 | zinc-aluminum-layered | 1 |
| 90 | nonimmersed | 1 |
| 91 | antithrombin-treated | 1 |
| 92 | renal-ablated | 1 |
| 93 | 3',4',5'-hydroxylated | 3 |
| 94 | yeast-secreted | 2 |
| 95 | therapeutic/treatment-oriented | 1 |
| 96 | minimal/resolved | 5 |
| 97 | intestinalized | 1 |
| 98 | ribozyme-catalyzed | 1 |
| 99 | 1300-fold | 1 |
| 100 | four-round | 1 |
| 101 | chromorhizae | 1 |
| 102 | don-3-o-glucoside | 1 |
| 103 | polidesossiribonucleotide | 1 |
| 104 | graphitic-like | 1 |
| 105 | petroleum-like | 1 |
| 106 | immunoprecipitable | 1 |
| 107 | high/upper-middle | 1 |
| 108 | juggle | 1 |
| 109 | mandelonitrile | 2 |
| 110 | diaminoanisole | 1 |
| 111 | miltiradiene | 1 |
| 112 | dansylglycine | 1 |
| 113 | hdl-phosphatidylcholine | 1 |
| 114 | n-methyl-p-phenylenediamine | 1 |
| 115 | murrayazolinine | 1 |
| 116 | bromopterosine | 1 |
| 117 | fentanyl-xylazine | 1 |
| 118 | dimethylhdrazine | 1 |
| 119 | atone | 1 |
| 120 | 5,6-dihydroxy-7-methoxyflavone | 1 |
| 121 | high-volume/low-pressure | 1 |
| 122 | citrate-phosphate-dextrose | 1 |
| 123 | masticate | 1 |
| 124 | 1,3-diphosphoglycerate | 1 |
| 125 | compensate | 366 |
| 126 | overcompensate | 2 |
| 127 | auscultate | 3 |
| 128 | pre-graduate | 1 |
| 129 | araldite | 1 |
| 130 | additive-additive | 1 |
| 131 | metabolic/digestive | 1 |
| 132 | 10ng/g | 1 |
| 133 | time-to-ecg | 1 |
| 134 | 69.3mg | 1 |
| 135 | side-lining | 1 |
| 136 | water-preferring | 1 |
| 137 | scytonemin-rich | 1 |
| 138 | set-i | 1 |
| 139 | 156min/week | 1 |
| 140 | duty/work | 1 |
| 141 | 1.89-l | 2 |
| 142 | 102.5g/l | 1 |
| 143 | nod/scid/γ-null | 1 |
| 144 | 600.0ng/ml | 1 |
| 145 | 2500.00ng/ml | 1 |
| 146 | 10,000pg/ml | 1 |
| 147 | 12500µg/ml | 1 |
| 148 | 1562µg/ml | 1 |
| 149 | 18.8ml | 1 |
| 150 | 3-amino-5-imino-5,8-dihydronaphthalen-2-ol | 1 |
| 151 | 11-cis-retinol | 1 |
| 152 | dilated-hcm | 1 |
| 153 | 1±0.1mm | 1 |
| 154 | 6.25mm | 1 |
| 155 | 22-nm | 1 |
| 156 | biculturalism | 1 |
| 157 | thiopental-rocuronium | 1 |
| 158 | intervention-driven | 1 |
| 159 | poly-alpha-olefin | 1 |
| 160 | phenythoin | 1 |
| 161 | placebo/peginterferon-alfa-2a/ribavirin | 1 |
| 162 | 'presentation | 1 |
| 163 | cis-dimerization | 2 |
| 164 | considertion | 1 |
| 165 | acupoint-moximustion | 1 |
| 166 | oblivion | 1 |
| 167 | β-pbo | 1 |
| 168 | 105euro | 1 |
| 169 | od+hp | 1 |
| 170 | folate-mh-aunp | 2 |
| 171 | simmer | 1 |
| 172 | rfviii-water | 1 |
| 173 | 1ml/kg/hr | 1 |
| 174 | 0.5ml/kg/hr | 1 |
| 175 | per-doctor | 1 |
| 176 | disfavor | 9 |
| 177 | ndsr | 1 |
| 178 | 80μg/hour | 1 |
| 179 | hypopnoeas | 1 |
| 180 | non-tcfas | 1 |
| 181 | goas | 1 |
| 182 | 29-month-olds | 1 |
| 183 | parklands | 2 |
| 184 | account.differences | 1 |
| 185 | prostaglandin-endoperoxides | 1 |
| 186 | substages | 3 |
| 187 | postchanges | 1 |
| 188 | subqualities | 1 |
| 189 | mitophagosomes | 1 |
| 190 | endosome/lysosomes | 1 |
| 191 | 3-methyl-pyrrolines | 1 |
| 192 | β-hydroxyynones | 1 |
| 193 | irregular-shapes | 1 |
| 194 | canals/isthmuses | 1 |
| 195 | silicoarsenates | 1 |
| 196 | schizoites | 1 |
| 197 | supercomplexes | 3 |
| 198 | big-bags | 1 |
| 199 | gangs | 1 |
| 200 | microsticks | 1 |
| 201 | 133mls | 1 |
| 202 | placebo.implications | 1 |
| 203 | micro-bars | 2 |
| 204 | smokers/ex-smokers/non-smokers | 1 |
| 205 | chito-oligomers | 1 |
| 206 | antinauseants | 1 |
| 207 | puiggrós | 1 |
| 208 | over-correct | 1 |
| 209 | half-height | 1 |
| 210 | healthvault | 2 |
| 211 | intensity-invariant | 1 |
| 212 | asa-resistant | 1 |
| 213 | grk2-dependent | 1 |
| 214 | account | 6,186 |
| 215 | risk-adjust | 2 |
| 216 | noti-cut | 1 |
| 217 | 37.87hu | 1 |
| 218 | psc-bppv | 3 |
| 219 | sorafenib-cryorx | 1 |
| 220 | qualify | 185 |
| 221 | euro41,110/qaly | 1 |
| 222 | euro43,614/qaly | 1 |
| 223 | euro51,106/qaly | 1 |
| 224 | barbour-stoenner-kelly | 1 |
| 225 | mid-sternotomy | 1 |
| 226 | karma-deed-heredity | 1 |
| 227 | nitrosatability | 1 |
| 228 | 5,8-epoxy | 1 |
| 229 | 9α-hydroxy | 1 |
| 230 | 45× | 1 |
| 231 | 7.44° | 1 |